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Abstract
Drug medications inevitably affect not only their intended protein targets but also other proteins as well. In this study we
examined the hypothesis that drugs that share the same therapeutic effect also share a common therapeutic mechanism by
targeting not only known drug targets, but also by interacting unexpectedly on the same cryptic targets. By constructing
and mining an Alzheimer’s disease (AD) drug-oriented chemical-protein interactome (CPI) using a matrix of 10 drug
molecules known to treat AD towards 401 human protein pockets, we found that such cryptic targets exist. We recovered
from CPI the only validated therapeutic target of AD, acetylcholinesterase (ACHE), and highlighted several other putative
targets. For example, we discovered that estrogen receptor (ER) and histone deacetylase (HDAC), which have recently been
identified as two new therapeutic targets of AD, might already have been targeted by the marketed AD drugs. We further
established that the CPI profile of a drug can reflect its interacting character towards multi-protein sets, and that drugs with
the same therapeutic attribute will share a similar interacting profile. These findings indicate that the CPI could represent
the landscape of chemical-protein interactions and uncover ‘‘behind-the-scenes’’ aspects of the therapeutic mechanisms of
existing drugs, providing testable hypotheses of the key nodes for network pharmacology or brand new drug targets for
one-target pharmacology paradigm.
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Introduction
Drug molecules inevitably affect not only their intended protein
targets but also other ‘‘off-target’’ proteins as well [1]. These
unexpected targets could, in some cases, mediate the physiological
effect of a drug, even if the drug is designed specifically to target
one particular protein [2]. Several antipsychotics, for example,
could trigger similar downstream molecular events when added to
the cell culture even without their target, the dopamine receptor,
expressed in it [3]. It is generally accepted that chemical-protein
interaction is the primary step in triggering molecular events in the
biological system when a drug is administered. The identification
of unexpected drug-protein interactions could therefore lead to the
discovery of new therapeutic targets and therapeutic pathways.
There are several strategies in mining such unexpected off-targets,
e.g., building new chemical-protein linkages in the known
therapeutic target space [2,4], investigating the pocket shape
[5,6] or sequence identity [7] between the off-target and the
known drug target. All these strategies operate on the narrow
space of the known drug targets, which represent only a small
portion of all human protein space.
Several ‘fishing’ techniques such as BIACORE [8], drug
affinity pull-down [9], drug affinity responsive target stability [10]
and quantitative proteomics based affinity enrichment [11] can
also assess the unexpected drug-protein interactions from a wider
protein space. Although not offering a systematic and convincing
evaluation of specificity and sensitivity in identifying true or false
bindings [12,13], docking one drug to a multi-protein set has
been a logical approach to ‘fishing’ unexpected targets. However,
none of the ‘fishing’ techniques described above offer the
dramatic progress recently achieved by transcriptomics [3],
metabolomics [14] and proteomics [15] in systematically
uncovering the molecular events following the administration of
a drug into the biological system. One reason might be the
inaccuracy of the scoring functions in the ‘fishing’ methodologies.
There is no guarantee, for instance, that if the docking score of
drug A to protein P1 is lower than A to P2, that P1 has a greater
affinity to A than P2 [16]. We therefore hypothesized that
investigating the relative strengths of chemical-protein interac-
tions from the ‘-omics’ viewpoint would be much more
meaningful than merely comparing the absolute values of a
drug’s effect on two proteins based on some certain scoring
function. Our second hypothesis was that drugs sharing the same
therapeutic effect also share the same therapeutic mechanisms by
targeting not only on the known target, but also on the same
unexpected targets. If the first hypothesis is correct, a more
accurate scoring method could be developed that could be
applied to the confirmation of the second hypothesis. The two
hypotheses require an overview of the drug-protein bindings at
the chemical-protein interactomics level.
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therefore introduced in this research, which has successfully been
applied in identifying unexpected drug-protein bindings in adverse
drug reactions [17]. To test the usefulness of this chemical-protein
interactome (CPI) technique on the therapeutic target mining in
an effective but low cost way, we chose the DOCK program [18]
to construct an in silico CPI. We first prepared 10 drug molecules
known to treat Alzheimer disease (AD) and 47 drug molecules
chosen randomly from Drugbank [19] as the ‘case’ and ‘control’
drugs, hypothesizing that clear differences between the interaction
profile of case and control drugs to multi-protein could be
observed. The target-mining strategy using this ‘-omics’ data was
based on the premise that if the protein was intensively targeted by
AD drugs, but did not tend to be targeted by the control drugs it
should be prioritized and be measured for its potential therapeutic
benefit to AD.
Results
Identifying the True Chemical-Protein Interactions Using
a Corrected Scoring Method
The docking scores are insufficient to assess absolute chemical-
protein interaction strength [16], which might explain why some
inverse docking techniques [12,13] are not widely used in
identifying unexpected bindings. To test the performance of our
optimization strategies on the drug-protein scorings, selected drug
targets from DrugBank [19] and their corresponding structures
from the Protein Databank (PDB). Each of the proteins was known
to be targeted by at least three FDA-approved drugs with co-
crystallized ligands occupying the functional sites. These ligands
were also chosen as probe molecules. Pockets without co-
crystallized ligands or with heme were excluded, leaving 46
proteins containing 48 pockets for the construction of the test CPI.
An in silico ‘hybridization’ was performed using DOCK program
[18]. Ligands too large to be docked into the pocket of every
protein were excluded. In all, an interactome of 44 ligands towards
48 protein pockets were generated in the form of a docking score
matrix of 48644 elements.
A 2-directional Z-transformation (2DIZ) was then applied to
transform the docking score matrix into a Z9-score matrix, where
the docking scores were normalized for each drug [20] and then
for each protein. Here the original ligand-protein bindings in PDB
structures were defined as true bindings, and the others classified
as unidentified bindings. The validity of the different scoring
systems in separating true and unidentified bindings was expressed
in the form of ROC curves (Fig. 1). Being close to the reference
line, the docking score matrix achieved a poor separating power.
However, using the 2DIZ made the AUC reached as high as 0.82.
The performance of Z-scores [17] was generally between the two.
The predictive accuracy of the Z9-scores may, in fact, be much
higher, since some of the unidentified bindings whose Z9-scores
were particularly low, might have occurred in any case, and
therefore been regarded as false positives. For example, the Z9-
score between retinoic acid receptor gamma-2 (1EXX) and
retinoic acid (REA) was -3.1, the lowest Z9-score of all drug-
protein bindings, was always classified as the true binding while
changing the classifying threshold. However, REA was originally
embedded in retinoic acid receptor RXR-alpha (1FBY) but not in
1EXX, so the binding of REA to 1EXX was always regarded as a
false positive according to the definition of true bindings.
Nevertheless, even with this biased evaluation, Z9-scores for 69%
of the true bindings compared with only 31% of the unidentified
bindings were less than 20.48, which was the threshold when the
absolute value of the differential coefficient of the ROC curve
reached its minimum, and the sensitivity and specificity are nearly
the same. A sensitivity of 0.70 and a specificity of 0.73 is
achievable when the threshold is set at 20.48, denoting that a Z9-
score less or greater than 20.48 indicates whether or not a binding
is likely to be the true binding.
Linear Model of the Chemical-Protein Interactome
Scoring
To give a reasonable explanation to why the Z9-score, not
docking score, is more suitable to represent chemical-protein
interactions, we put forward a linear model that a docking score
Figure 1. ROC curves representing the power for classifying true and unidentified bindings using docking score, Z-score and Z9-
score respectively. The AUC was 0.67, 0.77 and 0.82 for the three scoring systems.
doi:10.1371/journal.pone.0009568.g001
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Xij~mzaizbjz(ab)ij, ð1Þ
where m is the mean of docking scores, ai and bj are the assessment
of the endogenous contributions of protein factor i and ligand
factor j respectively; (ab)ij is the interactive effect of the two factors,
which reflects the true nature of the chemical-protein affinity. Both
the ligand and the protein factors are considered as the random
effect. Comparing the variances of these effects within the example
CPI above, we found that the protein and the ligand effects
contributed largely to the variances of the docking scores, and
dominated the interactive effect significantly. The mean squares
ratios (F values) of the protein and the ligand effect towards the
interactive effect are 11.1 (p=4.2E-67) and 65.8 (p=0.0)
respectively (File S1). After applying 2DIZ however, the protein
and the ligand factors that contribute to docking scoring are
eliminated and the Z9-scores are as follows (see deducing
procedures in File S1):
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in which denotes that b is the mean of all the interactive effects
within the matrix. We can see from the above equations that the
Z9-score is determined solely by the chemical-protein interactive
effect when the elements in the docking score matrix approach
positive infinity.
Constructing the AD Drug-Oriented Chemical-Protein
Interactome
Based on the reliability of the Z9-score in specifying true and
unidentified bindings, we have initiated an AD drug-oriented CPI
that is independent of the test CPI. The chemicals selected here
were seven parent AD drugs and three of their major derivatives.
To avoid biases in the CPI assessment, we confirmed that the
seven drugs did not share significant chemical features (Fig. 2a).
They were then ‘hybridized’ onto 401 protein pockets (Table S1)
using DOCK program to generate a case CPI consisting of
docking-scores of 401610 relations. These pockets were derived
from third-party databases [19,21,22,23,24] of protein targets,
which were in agreement with the target using pre-defined criteria.
To make sure that this target set was not enriched for AD related
pathway, we performed KEGG pathway enrichment for all these
401 proteins using DAVID tools [25]. Seven pathways were
enriched whose FDR is less than 0.1, but none of them are
significantly associated with AD. The control CPI with 401647
relations was obtained simultaneously through docking all 47
control molecules onto 401 pockets. These 47 drug molecules were
randomly chosen from Drugbank, A joint CPI was constructed,
and after applying the 2DIZ, the interaction strengths were
transformed into a joint Z9-score matrix (401657 relations). It was
then reverted into the AD drug-oriented CPI and the control CPI.
For each protein in the CPI, we determined whether they could or
could not be targeted by a particular compound if the Z9-score of
the interaction was less than or greater than the 20.48. As
indicated earlier, Z9-scores beyond this threshold captured 70% of
the true bindings and enriched more than three-fold as compared
with the unidentified bindings, and the non-parameter hypothesis
test we used in the subsequent assessment only required
information of this binomial pattern.
Prioritizing Accredited and Unexpected Therapeutic
Targets of AD from the CPI
To identify proteins preferentially interacting with the case
drugs, we performed Fisher’s exact tests for every protein in
comparison to the control. The significance (2-sided) for each of
the proteins with relative resk (RR) value (see Methods)
exceeding one were then calculated and were used as a measure
to prioritize the potential drug targets. Proteins with p values less
than 0.01 were highlighted (Fig. 2b and Table 1). Arginase-1
achieved the lowest p value (p=4.28E-06). This enzyme is
involved in the arginine-NO pathway [26], which has just been
discovered to be involved in AD pathogenesis [27]. The accredited
drug target, acetylcholinesterase (AChE), achieved a p value of
1.3E-3, as 8 of 10 case drugs tended to interact with it whereas
only 11 of 47 control drugs bind it. Surprisingly, we discovered
that two recently identified therapeutic target families of
neurodegenerative disease, the histone deacetylase (HDAC) family
and estrogen receptor (ER) family, might have already been
involved in the therapeutic pathways of these marketed AD drugs.
Both the representative protein of these two families achieved the
statistically significant p values (Table 1), indicating that they are
preferably targeted by case drugs than control drugs.
HDACs, the recently identified therapeutic targets for neuro-
degenerative diseases [28,29,30,31], catalyze the deacetylation
reaction of N
6-acetyl-lysine of histone. Notably, several biochem-
ical similarities were found between the HDAC and the AChE.
For example, the hydrolyzation of acetylcholine catalyzed by
AChE is another form of deacetylation. Histidine residue and a
Zn
2+ are involved in the catalytic mechanism of HDAC [32],
whereas His447 is also the catalyzing residue in acetylcholine
hydrolyzation [33] and the enzyme activity of AChE can be
significantly boosted by adding Zn
2+ cation [34]. These facts
indicate similarities in their catalytic mechanisms. Furthermore, A
pocket comparison algorithm, SiteSorter, raised a contact
similarity score of 0.14 between the active sites of these two
enzymes, indicating that there are similarities between the nature
of the contacts each site makes with its co-crystallized ligand [35].
To validate the similarity between these two enzymes, we chose
another docking program, AutoDock [36], to generate a more
comprehensive interactome of two enzymes toward inhibitors and
their substrates. Firstly, we chose the substrate of AChE, the
acetylcholine, to run a pre-test. AutoDock was able to correctly
dock it to the active center of AChE [37] with its acetyl group
interacting with two catalyzing residues of AChE (Fig. S1) using
the docking parameters as described in the Methods section. We
also confirmed that an inhibitor of HDAC, trichostatin A (TSA)
could be docked to the correct position compared with that of the
co-crystal ligand (RMSD,0.5). We then chose another HDAC
Alzheimer Polypharmacology
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drug molecules to constitute a ‘probe’ set, which was to ‘hybridize’
onto the two proteins. A control protein, HLA-B*5703, was
randomly chosen, hence a CPI of 1363 relations was constructed.
The Pearson correlation coefficient (PCC) between the docking
scores of AChE and HDAC7 towards 13 probes was 0.90
(p=3.5e-5, Fig. 3a), whereas the PCC between AChE and HLA-
B*5703 was 0.62 (p=0.024, Fig. 3b). When we randomly chose
50 other molecules from DrugBank (Table S2) to constitute a
control probe set, the PCC was 0.60 between AChE and HDAC7,
and 0.73 between AChE and HLA-B*5703 respectively (Fig. 3c,
d), indicating that correlation between the interaction profiles was
only high given the following two conditions: i) between AChE
and HDAC7; ii) using only ligands of AChE or HDAC as the
probe. Other members of HDAC family, including human
HDAC4, HDAC8 and a yeast HDAC, also showed significant
correlation of their interaction profiles with AChE (Table S3).
However, neither similarity in pocket shape (Fig. 2b) nor
significant sequence identity in binding site (Fig. S2) could be
observed between them, implying that the discovery of HDAC
could not be made by just comparing the structure or sequence.
We can see that the similarity between the pocket of HDAC7 and
the AChE is not determined by the pocket shape, but by their
interacting pattern with only the probe molecules, namely the AD
drugs and the HDAC inhibitors.
The successful recovery of both validated and candidate drug
targets of AD, which catalyze similar deacetylating reactions and
share a similar interaction profile with probe molecules, is not
likely to be achieved by chance. In addition, ERa and ERb were
also highlighted. The ligands of ERa and ERb are reported to
have neuroprotective and anti-inflammatory effects [38,39] and
are promising for AD therapy [40]. They might be the behind-the-
scene therapeutic targets of currently marketed AD drugs. Finally,
we could thus infer that other proteins highlighted along with these
proteins might also be involved in the therapeutic mechanisms of
AD, and might serve as the putative therapeutic targets. For
example, inositol monophosphatase, which interacts unexpectedly
with seven marketed AD drug molecules (p=3.2E-3), is signifi-
cantly up-regulated in the AD brain and may be responsible for
the pathogenesis of AD [41]. Hence the interactions of AD drug
inositol monophosphatase need further investigating.
The Reliability of the CPI
To test the reliability of the CPI and to better mimic the real
situation of the drug space, we chose (from Drugbank) a control set
comprising 63 schizophrenia drug molecules (Table S4) together
with the original 10 AD drug molecules. All of the 73 drug
molecules where then ‘hybridized’ onto another published target
set to construct a matrix with 73*815 elements. These 63
schizophrenia drug molecules were taken from Drugbank using
Figure 2. Constructing and mining an AD drug-oriented chemical-protein interactome. (a) Structures of 10 case drug molecules. Drug
names followed by numbers indicate the derivatives. (b) Interactome of these 10 drug molecules towards 15 highlighted proteins in Table 1.
Proteins are represented by their PDB IDs. Blue, red or white squares represent a Z9-value less than, greater than or equal to zero. Deeper color
denotes the greater absolute value. Missing value is presented as a grey box. The accredited drug target of AD (human AChE) is marked with 1F8U.
The newly candidate therapeutic target of AD, human HDAC7, is marked with 3C0Z. Binding models of an AD drug, physostigmine, to the pockets of
the known (AChE) and unexpected (HDAC7) therapeutic targets of AD are enlarged. Though the shapes and the amino acids sequence of the two
pockets are different, the drug accommodates to the two pockets both with steric complementarity and low binding free energy estimated by
AutoDock.
doi:10.1371/journal.pone.0009568.g002
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another because all of them could treat the schizophrenia, which is
a relevant disease to AD, but the drugs were not known to be
related to AD. Separating the AD drugs from these closely related
drugs will definitely demonstrate CPI’s ability of separating AD
drugs from other unrelated drugs. Similar procedures were applied
to perform Fisher’s exact test for each protein. Proteins with p
values less than 0.05 were selected for further investigation
(Table 2). Three AChEs (1GPK, 1GQS and 2ACE) were
included in these 85 highlighted proteins, which showed a
significant enrichment from all six AChEs in total 815 proteins
(Fisher’s exact test p=0.019). No HDAC protein were highlighted,
however, two estrogen receptors (1QKT and 1R5K) and an
inosine phosphate (1I9Z) were still being highlighted. In general,
even with completely different control set and target set, most of
the AD related proteins could still be recalled.
CPI Profile of a Drug Reflects Its Therapeutic Effect of AD
One of the concepts of network pharmacology [1] is that drug
effect can be mediated by the interactions among drugs towards
multiple proteins. Hence drugs sharing the same therapeutic effect
would not only share the same drug targets, but might also display a
similarityintheirinteractingprofile towardsamulti-proteinset.Ifthis
similarity can be demonstrated from CPI vectors, the efficacy of CPI
could be broadened, e.g., the drug efficacy could be predicted by
u s i n gt h ed o c k i n gs c o r ev e c t o ro fad r u gt o w a r d sm u l t i - p r o t e i ns e t .
In the above section, the methodology could highlight the AD
related proteins based on the 63 control drugs. Distinguishing AD
drugs from the drugs of this AD relevant disease could be a
reference of its power in separating drugs of other diseases. Here
we applied the principle component analysis (PCA) to explore
whether AD drugs could be separated from schizophrenia drugs
based on their docking score vectors. The first two components
could explain 80.8% of the total variances, and the 10 AD drugs
and 63 control drugs could mostly be separated linearly
(accuracy=93.2%, Fig. 4). The four ‘false positive’ points from
left to right were loxapine, olanzapine, clozapine and molindone
respectively. They were not only quite close to the AD drugs in
Fig. 4, but were also found to be closely linked to AD in their
therapeutic effects. For example, olanzapine was effective in
treating psychotic and behavioral disturbances in AD [42];
loxapine and molindone had the unlabeled effect of treating
psychosis/agitation related to Alzheimer’s dementia (http://www.
merck.com/mmpe/lexicomp/loxapine.html, http://www.merck.
com/mmpe/lexicomp/molindone.html); Clozapine was found
for the treatment of agitated-depressed patients with cognitive
impairment [43]. The PCA results denoted that the CPI profile of
a drug could reflect its therapeutic effect.
Discussion
It is not sufficient to conduct an accurate assessment of chemical-
protein bindings based solely on the original docking scores [16].
From our data we established that the scoring for both the inverse
dock [12] and the classical docking method could be improved
through systematically mining the CPI. When the Z-transformation
was applied for drug j towards multi-protein, the effect of bj was
eliminated, leaving only the effect of the ai and (ab)ij;w h e nZ -
transformation was applied again for protein i towards multi-drugs
on the Z-score, the effect of ai was eliminated, thus only the effect of
drug-protein interaction was left. For the inverse docking, the
scoring will be inaccurate when ai dominates the (ab)ij. In other
word, one cannot be sure that P1 is more affinitive to drug A than
P2 if P1 ranks higher than P2 in the docking score list of A towards
multi-protein. With virtual screening, on the other hand, it is not
certain that D1 is more affinitive to P than D2 when D1 ranks
higher than D2 in the scoring list of P’s targeting by multi-drug,
because bj sometimes dominates (ab)ij. Based on the landscape of
the CPI, one can make more reliable judgments for drug-protein
interactions. Virtual screening can be considerably improved by the
use of the MASC method [20], but the 2DIZ transformation was
much more effective than this method on the CPI data (Fig. 1). It is
anticipated that target screening should consider the difference in
the interactome profiles of the library proteins towards multiple
drugs; whereas compound screening should investigate the
distribution of library molecules towards multiple proteins. Ideally,
a CPI comprising of all chemicals and all human macro molecules
would be constructed, as deduced in the linear model, the chemical-
protein interactive effect would solely be represented by Z9-score if
the chemical and target number approached positive infinity.
There may be undiscovered mechanisms which are responsible for
the therapeutic effect of the existing AD drugs, and a combined effect
on multiple targets may exist. This work demonstrates that the CPI can
generate testable hypotheses about the behind-the-scene pharmacology
of the existing drugs other than AD drugs. With the help of CPI,
candidate key nodes for network pharmacology [1] and new drug
targets for one-target pharmacology could be identified. There could
be a low cost, high throughput pre-screening step followed by ‘wet’
experiments, and recall of the off-targets would not be hindered by the
dissimilarity with the known target in either pocket shape [5,6] or
sequence identity [7]. The identification of unexpected but desired
bindings adds to the feasibility of identifying unexpected and unwanted
bindings for adverse drug reactions using the CPI methodology [17].
By constructing and mining the CPI, it will be possible not only to
harvest unexpected bindings, but also to predict the therapeutic effect
or the adverse effect of a drug [17] by uploading the small molecule to a
server to construct its CPI signature towards available a human macro
Table 1. Proteins highlighted from AD drug-oriented CPI
using 401 protein set.
PDB ID Protein Name ab c d RR Sig.
2AEB Arginase-1 10 10 0 37 4.278E-06
1F8U Acetylcholinesterase 8 11 2 36 8.00 0.001314
1VJB Estrogen-related receptor gamma 8 11 2 35 7.79 0.001512
1R5K Estrogen receptor 8 11 2 34 7.58 0.001745
3C0Z Histone deacetylase 7 6 5 1 22 12.55 0.002037
1F5F Sex hormone-binding globulin 8 9 2 28 7.06 0.002187
2BRO Serine/threonine-protein kinase
Chk1
7 9 3 38 5.98 0.003079
1IMB Inositol monophosphatase 7 11 2 36 7.39 0.003179
1YOL Proto-oncogene tyrosine-protein
kinase Src
7 10 3 36 5.35 0.005525
2C6Q GMP reductase 2 7 11 3 36 5.06 0.007531
1G8Q CD81 antigen 7 11 3 35 4.93 0.008457
1Z8G Serine protease hepsin 7 11 3 35 4.93 0.008457
1U54 Activated CDC42 kinase 1 8 14 2 33 6.36 0.009075
1B1C NADPH–cytochrome P450
reductase
8 14 2 33 6.36 0.009075
1EZF Squalene synthetase 7 11 3 34 4.80 0.009514
For each protein, a, b, c, d values, represents the number of binding (a or b)a n d
non-binding (c or d) by case drug molecules or control drug molecules
respectively. The two-sided p values were estimated from Fisher’s exact test.
doi:10.1371/journal.pone.0009568.t001
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therapeutic area is unknown, can be compared with the CPI signatures
of the existing drugs whose indications are known, providing a
potential methodologyfor pharmaceutical innovation.This is similar to
the process of uploading the expression profile of a cell treated by a
drug totheconnectivitymap [3],comparingitwith the pre-constructed
transcriptomic data of the cell treated with different drugs, and then
making a functional linkage between the user’s drug and the drugs in
the server’s database. The expression profile of the cell provides a rich
description of cell status; whereas the CPI describes the primary step
when a drug is added to the biological system [11,45]. Knowing which
proteins’ function is affected by a drug is fundamental, for it could
explain the downstream molecular events at the source. The
comparison and the combination effect of using two ‘-omics’ platforms
in predicting the therapeutic effects and adverse effects of particular
drugs will be thoroughly evaluated in follow-up research.
As well as the methodology of CPI introduced above, our
research could also inform the search for therapeutic drugs for
AD. It is known that several HDAC inhibitors are now in clinical
trials aiming at AD therapy, but delivery of the drug to the brain
Figure 3. Correlations of docking scores among AChE, HDAC7 and HLA-B*5703 towards probe molecules. The assumed normality and
equal variances of docking scores within each group could not be rejectedin statistical tests. The PDB ID of the representative structures of AChE,
HDAC7 and HLA-B*5703 were 1F8U, 3Z0Y and 2BVP respectively. See Table S2 for the detail of their interactomes. (a, b) Correlations of docking
scores among AChE, HDAC7 and HLA-B*5703 towards 13 probe molecules. (c, d) Correlations of docking scores among these three proteins toward
50 control probes.
doi:10.1371/journal.pone.0009568.g003
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PDB ID Protein Name ab cdRR Sig.
1Z93 Carbonic anhydrase 3 7 6 3 52 9.87 0.000162
1GPK Acetylcholinesterase 9 15 1 43 16.50 0.000205
1FKG Peptidyl-prolyl cis-trans isomerase FKBP1A 8 10 2 43 10.00 0.000356
1J02 Heme oxygenase 1 7 9 2 47 10.72 0.000441
1FVG Peptide methionine sulfoxide reductase 6 5 3 47 9.09 0.000546
1G8Q CD81 antigen 7 9 3 51 7.88 0.000763
1WXC Tyrosinase 4 0 6 41 7.83 0.000840
1EFH Bile salt sulfotransferase 4 1 6 58 8.53 0.001125
1C9H Peptidyl-prolyl cis-trans isomerase FKBP1B 6 6 4 53 7.13 0.001144
1R5K Estrogen receptor 7 11 3 49 6.74 0.001926
1DBK Ig gamma-1 chain C region secreted form 6 6 4 47 6.38 0.001941
1E4X TAB2 8 15 2 41 7.48 0.002271
1ME8 Inosine-59-monophosphate dehydrogenase 7 12 3 50 6.51 0.002405
1GQS Acetylcholinesterase 8 14 2 38 7.27 0.002511
1NR5 Pentafunctional AROM polypeptide 6 8 4 53 6.11 0.002797
2BFW GlgA glycogen synthase 7 12 3 48 6.26 0.002900
1C8P Cytokine receptor common subunit beta 6 8 4 52 6.00 0.003032
2DBL Ig gamma-1 chain C region secreted form 6 8 4 52 6.00 0.003032
1DBM Ig gamma-1 chain C region secreted form 6 7 4 47 5.88 0.003078
1DAR Elongation factor G 7 10 3 40 5.90 0.003489
1JCN Inosine-59-monophosphate dehydrogenase 1 7 12 3 46 6.02 0.003515
1FKF Peptidyl-prolyl cis-trans isomerase FKBP1A 6 8 4 50 5.79 0.003574
1ELA Chymotrypsin-like elastase family member 1 8 18 2 42 6.77 0.004085
1BZM Carbonic anhydrase 1 6 7 4 42 5.31 0.004893
1HFW L-asparaginase 6 7 4 42 5.31 0.004893
1DBB Ig gamma-1 chain C region secreted form 6 8 4 46 5.36 0.005035
2EU9 Dual specificity protein kinase CLK3 8 18 2 40 6.46 0.005096
1C41 6,7-dimethyl-8-ribityllumazine synthase 6 9 4 49 5.30 0.005591
1YTV Vasopressin V1a receptor 7 14 3 46 5.44 0.006041
1CPS Carboxypeptidase A1 6 10 4 52 5.25 0.006115
1H8P_3 Seminal plasma protein PDC-109 4 2 5 40 6.00 0.006322
2BU5 [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2,
mitochondrial
5 5 5 47 5.20 0.006645
2FKY Kinesin-like protein KIF11 5 5 5 47 5.20 0.006645
1TNJ Cationic trypsin 5 4 5 40 5.00 0.006978
1ZZD Ribonucleoside-diphosphate reductase large chain 1 5 5 5 46 5.10 0.007175
5CNA Concanavalin-A 6 8 3 35 5.43 0.007573
1MCR IMMUNOGLOBULIN LAMBDA DIMER MCG (LIGHT CHAIN) 6 10 4 48 4.88 0.008387
1GPM GMP synthase [glutamine-hydrolyzing] 5 7 5 53 4.83 0.010200
2HGS_2 Glutathione synthetase 5 7 5 53 4.83 0.010200
2CMD Malate dehydrogenase 3 1 7 51 6.21 0.011562
1JNW Pyridoxine/pyridoxamine 59-phosphate oxidase 5 7 5 51 4.67 0.011650
1UDH Uracil-DNA glycosylase 5 7 5 51 4.67 0.011650
2BYU 16.9 kDa class I heat shock protein 2 5 7 5 51 4.67 0.011650
1P8V_1 Platelet glycoprotein Ib alpha chain 6 10 4 44 4.50 0.011693
1I9Z Inositol-1,4,5-trisphosphate 5-phosphatase 1 6 11 4 47 4.50 0.012141
1GNX Beta-glucosidase 5 7 5 49 4.50 0.013353
2C6Q GMP reductase 2 6 12 4 49 4.42 0.013524
1AZM Carbonic anhydrase 1 5 5 5 38 4.30 0.013847
1FKI Peptidyl-prolyl cis-trans isomerase FKBP1A 6 12 4 48 4.33 0.014594
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how the existing AD drugs cross the blood brain barrier might
facilitate the design and development of HDAC inhibitors, or even
two-target drugs targeting AChE and HDACs to achieve a
combined therapeutic effect on AD.
Materials and Methods
Preparation of the Protein Pocket Set and the Ligand Set
for AD-Oriented CPI
Protein targets were obtained from third-party targetable
protein databases [19,21,22,23,24]. Every pocket had been
examined manually when constructing the protein set according
to the following criteria: Firstly, the species of the protein should be
confined to Homo Sapiens; secondly, the pocket must contain the co-
crystallized ligand to indicate the targetable state of the protein;
thirdly, the pocket should not contain missing residues; fourthly,
the protein set should not be redundant. Spheres whose radii
ranging from 1.1–1.4A ˚ were generated to fill in the pocket. A grid
box was constructed 3–5A ˚ departed from the balls. The case drugs
were derived from DrugBank, which were indicated for the
treatment of AD in the ‘‘Description, Pharmacology, Mechan-
ism_of_Action’’ fields of the FDA-approved drug table. Control
drugs were chosen randomly from DrugBank. The SMILES code
of the chemicals was retrieved from PubChem. The minimal
energy conformations of chemicals were simulated using COR-
PDB ID Protein Name ab cdRR Sig.
2CAB Carbonic anhydrase 1 4 4 5 45 5.00 0.015191
1BMA Chymotrypsin-like elastase family member 1 8 23 2 39 5.29 0.015779
1QKT Estrogen receptor 6 10 4 40 4.13 0.016597
1PTG 1-phosphatidylinositol phosphodiesterase 6 12 4 46 4.17 0.017042
5CPP Camphor 5-monooxygenase 8 21 2 35 5.10 0.017051
1AHA Ribosome-inactivating protein momordin I 4 5 5 49 4.80 0.018610
1ILH Nuclear receptor subfamily 1 group I member 2 6 12 4 44 4.00 0.019975
1NY3 MAP kinase-activated protein kinase 2 6 12 4 44 4.00 0.019975
1JQ9 Phospholipase A2 VRV-PL-VIIIa 6 13 4 47 4.03 0.019992
1PL7 Sorbitol dehydrogenase 6 11 4 40 3.88 0.021754
1TNH Cationic trypsin 4 5 6 53 4.37 0.021831
1D2F Protein malY 4 2 5 26 4.13 0.022041
2BO6 Mannosylglycerate synthase 6 13 4 45 3.87 0.023286
7YAS Hydroxynitrilase 6 11 4 39 3.79 0.023747
1F5F Sex hormone-binding globulin 7 13 3 34 4.32 0.024106
1A3G Branched-chain-amino-acid aminotransferase 4 5 6 51 4.22 0.024335
1II5 HYPOTHETICAL PROTEIN SLR1257 3 1 4 24 5.25 0.025306
1HNE Neutrophil elastase 7 17 3 43 4.47 0.025595
1JS3 Aromatic-L-amino-acid decarboxylase 5 11 4 49 4.14 0.026170
1Q1A NAD-dependent deacetylase HST2 5 10 5 52 3.80 0.027507
1Q3E Potassium/sodium hyperpolarization-activated cyclic
nucleotide-gated channel 2
5 10 5 52 3.80 0.027507
2ACE Acetylcholinesterase 7 16 3 38 4.16 0.027537
1CNY Carbonic anhydrase 2 4 6 6 54 4.00 0.030240
1DGD_1 2,2-dialkylglycine decarboxylase 5 9 5 46 3.64 0.030884
1K74_1 Retinoic acid receptor RXR-alpha 5 10 3 35 4.22 0.032835
2A3Z Wiskott-Aldrich syndrome protein 4 6 6 52 3.87 0.033525
2PK4 Plasminogen 4 6 6 52 3.87 0.033525
1GL5 Tyrosine-protein kinase Tec 7 20 3 42 3.89 0.033958
1DBJ Ig gamma-1 chain C region secreted form 5 9 5 44 3.50 0.035372
1YSC Carboxypeptidase Y 7 17 3 35 3.69 0.036841
1OIT Cell division protein kinase 2 4 7 6 55 3.70 0.039770
1AVN Carbonic anhydrase 2 5 10 5 46 3.40 0.040039
1CR1 DNA primase/helicase 5 10 5 46 3.40 0.040039
1HDK_2 Eosinophil lysophospholipase 4 5 5 36 3.64 0.043150
1IJE Elongation factor 1-alpha 4 7 6 51 3.45 0.048502
PDB IDs marked with a number indicate the pocket number. Refer to the note of Table 1 for the explanation of a, b, c, d and Sig.
doi:10.1371/journal.pone.0009568.t002
Table 2. Cont.
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added using Chimera [46].
Construction of the AD-Oriented CPI Using DOCK
The running of the DOCK program and the extraction of the
results were controlled by Perl and shell scripts on a Ubuntu
TM
Linux cluster. The overall docking score of a chemical-protein
interaction was calculated using simple energy calculations
(electrostatic and van der Waals) with all default parameters used.
According to our experience, all the distributions of docking scores
in CPI correspond to normal distribution if the data points
(docking score .0) are excluded. Docking scores greater than zero
were therefore treated as an abnormal value and were excluded.
Visualization of CPI scoring matrix was performed using java
Treeview [47]. Visualization of chemical-protein interactions were
realized using PyMOL.
The 2-Directional Z-Transformation
Before the 2-directional Z-transformation (2DIZ) was applied
to process the original docking-score matrix, a joint CPI
(401657 relations) comprising of a case matrix (401610
relations) and a control matrix (401647 relations) was
constructed. Here Xij represents the docking-scores of ligand j
to protein i in the joint matrix. Firstly, the Z-scores were
calculated as:
Zij~
Xij{Xj
SDXj
,
where Xj and SDXj are the mean and the standard deviation of
the docking score vector of ligand j. Then the Z-score vector for
each protein was normalized with the following formulas,
generating the Z9-score matrix.
Z0
ij~
Zij{Zi
SDZi
,
where Zi and SDZi are the mean and the standard deviation of
the Z-score vector of protein i.
Comparing the Variances of between-Subjects Effects
within the Test CPI
The type IV method was used to calculate the sum of squares.
The normality of the chemical-protein interactive effect was
guaranteed by the Kolmogorov-Smirnov test. The F value was
computed as MSc/MScp and MSp/MScp respectively, where MSc,
MSp and MScp denoted the mean squares of the ligand, protein
and the interactive effects.
Test for Interaction Differences between ‘‘Case’’ and
‘‘Control’’ Drugs for Each Protein
A chemical-protein interaction with Z9-score less or greater than
20.48 was defined as binding or non-binding. For protein i, ai, bi,
ci, di values, representing the number of binding (ai or bi) and non-
binding (ci or di) by case or control drug molecules respectively,
were counted and the relative risk (RR) value was calculated as
follows:
RRi~
ai
aizbi
  
cizdi
ci
  
:
Protein targets with a RR value exceeding one were chosen for
Fisher’s exact tests, which were carried using an R software
package [48].
Correlation Analysis of CPI Profiles among Protein
Targets
The highest absolute value of docking scores generated by
AutoDock4 [36] among 50 runs for each chemical-protein
interaction was chosen as a reference score. All the default
parameters were used when making grids and running AutoDock4,
except that the parameter of the genetic algorithm, ‘‘Maximum
Number of Evals’’, was set to 2,000,000. Tests of normality were
performed using the Kolmogorov-Smirnov test. Levene’s test was
applied to the test of equal variances. The Pearson correlation
coefficient r between protein X and Y was calculated, and the
assumption of r equals zero was tested using the t-test.
Supporting Information
Table S1 The 401 human protein pockets set.
Found at: doi:10.1371/journal.pone.0009568.s001 (0.41 MB
DOC)
Table S2 Interactome of probe molecules towards the tree
proteins.
Found at: doi:10.1371/journal.pone.0009568.s002 (0.13 MB
DOC)
Table S3 Interactome and correlations of docking scores among
AChE and other members of HDAC family towards 13 probes.
Found at: doi:10.1371/journal.pone.0009568.s003 (0.04 MB
DOC)
Table S4 Sixty two schizophrenia drug molecules.
Found at: doi:10.1371/journal.pone.0009568.s004 (0.05 MB
DOC)
Figure 4. The first two principle components plot of AD and
schizophrenia drugs based on their docking score vectors. The
figure demonstrates that 10 AD drugs (red) could be basically separated
from 63 schizophrenia drugs (blue) linearly.
doi:10.1371/journal.pone.0009568.g004
Alzheimer Polypharmacology
PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9568Figure S1 Visualization of the docking result of acetylcholine’s
interacting with the active center of AChE using AutoDock. The
acetyl of acetylcholine interacts with two catalyzing residues
(Ser203 and His447), which is accommodate to the catalytic
mechanism of AChE.
Found at: doi:10.1371/journal.pone.0009568.s005 (1.52 MB TIF)
Figure S2 Comparison of the binding site and sequence identity
in active site of AChE and HDAC7. (a, b) Comparison of the
docking result of physostigmine to the active site of human AChE
and hunan HDAC7. (c, d) Comparison of the docking result of
huperzine A to the active site of human AChE and hunan
HDAC7. Residues within 6A ˚ of the docked ligand of AChE (PDB
ID: 1F8U) are Asp74, Gly82, Thr83, Met85, Trp86, Gly120,
Gly121, Gly122, Phe123, Tyr124, Ser125, Gly126, Leu130,
Tyr133, Gln202, Ser203, Ala204, Phe295, Phe297, Tyr337,
Phe338, Tyr341, Trp439, Pro446, His447, Gly448 and Tyr449.
Residues within 6A ˚ of the docked ligand of HDAC7 (PDB ID:
3Z0Y) are His541, Pro542, Glu543, His544, Arg547, Asp626,
Pro667, His669, His670, Gly678, Phe679, Asp707, Val708,
His709, Phe738, Gly799, Phe800, Asp801, His806, Pro809,
Leu810, Gly811, Glu840, Gly841, Gly842 and His843. No
significant similarity could be observed within these amino acids
between the two proteins.
Found at: doi:10.1371/journal.pone.0009568.s006 (0.87 MB TIF)
File S1 Comparing the variances introduced by the ligands and
proteins respectively. Deducing procedures of elimination of the
protein and the ligand factors.
Found at: doi:10.1371/journal.pone.0009568.s007 (0.08 MB
DOC)
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